Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes

  • J Diabetes Investig. 2022 Dec;13(12):1958-1960. doi: 10.1111/jdi.13896.
Eiichi Araki  1  2 ,  Masaji Sakaguchi  1 ,  Kazuki Fukuda  1  2 ,  Tatsuya Kondo  1
Affiliations
  • 1. Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • 2. Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
PMID: 36039895 DOI: 10.1111/jdi.13896
Abstract

Triagonists of GLP-1R/ GIPR /GCGR, including SAR441255, bind to each receptor and induce specific effects through each receptor signaling pathway, thus result in weight loss and glycemic control in obese T2D animal models.

Products